Pfizer Reports 15% Decrease in Patient Enrollment in Phase 3 Ulcerative Colitis Trial; Enrollment Drops From 912 to 772 Patients; Trial Active But Not Recruiting; Primary Completion Date Revised to July 20, 2026
Pfizer Reports 15% Decrease in Patient Enrollment in Phase 3 Ulcerative Colitis Trial; Enrollment Drops From 912 to 772 Patients; Trial Active But Not Recruiting; Primary Completion Date Revised to July 20, 2026
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.